RIGI and skin cancer: High doses of the photocaged ligands can be applied by established areal injection methods in vivo and then activated by light specifically at the circumscribed site of the tumor.[45] Tumor‐targeted gamma‐irradiation and MAP kinase inhibition synergize with RIG‐I activation,[23, 24] further enhancing the combinatorial arsenal for effective immunotherapy of skin cancer.